In particular, metformin has been shown to modulate AMP-activated protein kinase (AMPK) activation via LKB1 with consequent inhibition of the mTOR pathway, which is crucial in cell growth and proliferation in CRC as in other cancer types. Here, MTOR is linked to cancer.